LL-37 Reference Guide

Compound Reference Overview

Field Value
Name LL-37
Reference Code LL-37
Category Healing & Recovery
Example Strength 5 mg (varies by formulation)
Reference Range 50–200 mcg daily (compiled protocol reference; investigational)
Frequency Once daily (protocol reference)
Key Safety Warning Immune Activation Risk: LL-37 is a potent immunomodulatory antimicrobial peptide and may exacerbate inflammatory or autoimmune activity in susceptible individuals. Start low and monitor symptoms.

Status: Not FDA-approved for general antimicrobial “support.” Use is investigational/off-label in many contexts.

Mechanism of Action (Educational)

LL-37 is a human cathelicidin antimicrobial peptide (host defense peptide) with broad-spectrum antimicrobial activity. It interacts with microbial membranes and can contribute to biofilm disruption and antimicrobial effects. LL-37 also exhibits immunomodulatory activity, which may influence inflammatory signaling depending on host context.

Indications (Investigational / Literature)

  • Antimicrobial support (investigational)
  • Wound healing support (investigational)
  • Immune modulation / biofilm-disruption frameworks (investigational)

Administration (Protocol Reference)

Parameter Details
Route Subcutaneous
Frequency Once daily
Injection Sites Abdomen; near affected area (site-dependent protocols vary)
Timing Any time; maintain consistent daily timing

Titration Schedule (Protocol Reference)

The following escalation model is provided for structured protocol formatting only and is not prescribing guidance. Conservative initiation is emphasized due to possible inflammatory activation in sensitive individuals.

  • Weeks 1–2: 50–100 mcg daily (start low)
  • Weeks 3+: 100–200 mcg daily (increase only if needed/tolerated)

Notes: Start at the low end and monitor for fatigue, flu-like symptoms, or inflammatory flare patterns.

Reconstitution & Concentration
(Mathematical Illustration Only)

The following reconstitution model is provided strictly for arithmetic illustration for research/compounded presentations. Commercial handling requirements may differ by manufacturer and formulation.

Parameter Value
Diluent Bacteriostatic water (example only)
Reconstitution Volume 2 mL (example only)
Resulting Concentration 2.5 mg/mL (example: 5 mg ÷ 2 mL)
Stability Up to 28 days refrigerated (varies by compounding standards)

Safety & Contraindications (Summary)

Contraindications / Avoid Use

  • Pregnancy or breastfeeding
  • Autoimmune or inflammatory disorders (relative contraindication; may exacerbate symptoms)

Drug / Program Interactions

  • Antibiotics (may be used in parallel in clinical antimicrobial frameworks; does not replace antibiotics)

Adverse Events

  • Injection site reactions
  • Transient flu-like symptoms
  • Fatigue / inflammatory flare pattern (in susceptible individuals)

Serious / Theoretical Risks

  • Autoimmune activation (theoretical / patient-dependent)
  • Hemolysis at extremely high exposures (theoretical risk; avoid high-dose escalation)

Monitoring (Protocol Reference)

  • Symptom response (local wound/skin response if applicable)
  • Inflammatory/autoimmune symptoms (fatigue, joint pain, rashes, flare patterns)
  • If prolonged use: CBC and inflammatory markers (context-dependent)

Mathematical Calculation Tool

The calculator below allows arithmetic concentration and volume calculations using variable vial strengths and reconstitution volumes. This tool is provided strictly for mathematical reference.

Peptide Reconstitution Calculator

For Educational & Professional Reference Only

⚠️ This is a mathematical reference tool only. No medical or dosing advice is provided.

Disclaimer

LL-37 is not FDA-approved for general antimicrobial support. This content is provided strictly as a pharmacologic and mathematical reference for educational and professional purposes. It does not constitute medical advice, prescribing guidance, diagnosis, or treatment recommendations. All clinical decisions must be made by a licensed healthcare professional in accordance with applicable regulations.

Reference Sources